DiaMedica Therapeutics Inc. (DMAC) Total Return Calculator with Dividends Reinvested

DiaMedica Therapeutics Inc.

Popular:

The total return for DiaMedica Therapeutics Inc. (DMAC) stock is +53.14% over the past 12 months. So far it's down 26.23% this year. The 5-year total return is -26.69%, meaning $10,000 invested in DMAC stock 5 years ago would be worth $7,331 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in DMAC 1 year ago, it would be worth $16,027 today — you'd have gained $6,027.

With Dividends Reinvested$16,027+60.27%

Price Only (No DRIP)$16,027+60.27%

Period2025-06-23 → 2026-06-18

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in DMAC

1Y$15,314+$5,314 (+53.1%)53.1% CAGR

3Y$14,962+$4,962 (+49.6%)14.4% CAGR

5Y$7,331-$2,669 (-26.7%)-6.0% CAGR

10Y$13,929+$3,929 (+39.3%)3.4% CAGR

15Y$1,424-$8,576 (-85.8%)-12.2% CAGR

20Y$1,424-$8,576 (-85.8%)-9.3% CAGR

30Y$1,424-$8,576 (-85.8%)-6.3% CAGR

DiaMedica Therapeutics Inc. did not pay dividends during this period. Total return = price return.

Loading DMAC total return...

As of 2026-06-22

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-26.23%	—	-26.23%	—	$7,377
1Y	+53.14%	53.14%	+53.14%	—	$15,314
3Y	+49.62%	14.37%	+49.62%	—	$14,962
5Y	-26.69%	-6.02%	-26.69%	—	$7,331
10Y	+39.29%	3.37%	+39.29%	—	$13,929
15Y	-85.76%	-12.19%	-85.76%	—	$1,424
20Y	-85.76%	-9.29%	-85.76%	—	$1,424
30Y	-85.76%	-6.29%	-85.76%	—	$1,424

Risk & Highlights

Best Year+127.27%2017

Worst Year-93.50%2014

Max Drawdown-43.24%2025-12-12 → 2026-06-10

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+0.25%	+0.25%	—	+0.41%	-0.2pp
2025	+44.46%	+44.46%	—	+16.64%	+27.8pp
2024	+91.87%	+91.87%	—	+24.00%	+67.9pp
2023	+91.89%	+91.89%	—	+24.81%	+67.1pp
2022	-59.28%	-59.28%	—	-19.95%	-39.3pp

DMAC outperformed the S&P 500 by 28.15pp over the past year (+53.14% vs +24.99%).

Loading summary...

DMAC Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
DMACDiaMedica Therapeutics Inc.	$315M	+3.0%	-26.2%	+53.1%	—	+49.6%	-26.7%	+39.3%
ATHAAthira Pharma, Inc.	$17M	—	-37.6%	+40.0%	—	-84.8%	-96.1%	-97.5%
ACMRACM Research, Inc.	$7.3B	+73.7%	+144.8%	+336.2%	—	+835.1%	+223.9%	+5775.4%
NERVMinerva Neurosciences, Inc.	$31M	-5.7%	+14.0%	+147.0%	—	-29.6%	-78.8%	-94.9%
ANIKAnika Therapeutics, Inc.	$193M	-3.5%	+54.2%	+29.9%	—	-46.8%	-63.9%	-71.0%
PRAXPraxis Precision Medicines, Inc.	$8.2B	-11.9%	-1.4%	+557.0%	—	+1611.0%	-12.5%	-32.3%
BIIBBiogen Inc.	$29.0B	+2.4%	+10.5%	+55.4%	—	-33.1%	-49.4%	-17.2%
ACADACADIA Pharmaceuticals Inc.	$3.7B	+4.5%	-17.3%	-5.8%	—	-9.3%	-16.9%	-42.2%
INVAInnoviva, Inc.	$1.7B	+3.2%	+13.2%	+4.8%	—	+75.4%	+68.7%	+101.2%
RAREUltragenyx Pharmaceutical Inc.	$2.7B	+13.4%	+16.3%	-26.5%	—	-45.3%	-71.1%	-49.7%
NKTRNektar Therapeutics	$1.2B	-10.9%	+40.4%	+608.2%	—	+639.2%	-76.1%	-73.3%

Compare:DMAC vs ATHA DMAC vs ACMR DMAC vs NERV DMAC vs ATHA vs ACMR

About DMAC Dividend Returns

DiaMedica Therapeutics Inc. (DMAC) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of DMAC over the past year?

DiaMedica Therapeutics Inc. (DMAC) delivered a return of 53.14% over the past year. Since DMAC does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in DMAC be worth today?

A $10,000 investment in DiaMedica Therapeutics Inc. one year ago would be worth $15,314 today, representing a gain of $5,314.

Q3Does DMAC pay dividends?

DiaMedica Therapeutics Inc. (DMAC) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For DMAC, the total return equals the price-only return.

Q4Did DMAC beat the S&P 500?

Yes, DiaMedica Therapeutics Inc. (DMAC) outperformed the S&P 500 by 28.15 percentage points over the past year. DMAC delivered a total return of 53.14%, compared to the S&P 500's 24.99%. This 28.15pp alpha means investors in DMAC earned more than a passive S&P 500 index fund.

Q5What is DMAC's worst drawdown?

DiaMedica Therapeutics Inc. (DMAC) experienced a maximum drawdown of -43.24% over the past year, declining from its peak on 2025-12-12 to its trough on 2026-06-10. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is DMAC's long-term total return over 10, 20, or 30 years?

Here are DiaMedica Therapeutics Inc. (DMAC)'s long-term returns with dividends reinvested. Over 10 years, the total return is 39.3% (3.4% CAGR) — $10,000 would have grown to $13,929. Over 20 years: -85.8% total return (-9.3% CAGR) — $10,000 → $1,424. Over 30 years: -85.8% total return (-6.3% CAGR) — $10,000 → $1,424. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was DMAC's best and worst year?

DiaMedica Therapeutics Inc.'s best calendar year was 2017 with a total return of 127.3%. Its worst year was 2014 with a total return of -93.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 220.8 percentage points.

How much would $100/month in DMAC be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →